Health and effects
Cannabinoids and Sleep onset latency
What studies can tell us about cannabinoids and Sleep onset latency, including human research, early evidence, and important limits.
The short answer
What does the research say about Sleep onset latency?
Researchers have studied cannabinoids in connection with Sleep onset latency. The current literature covers CBD and CBN. This page brings together 2 human-study sources and 1 research review. It includes 11 specific study findings from 3 sources. Human research is included, although its design and scope vary. There is no single answer that applies to every cannabinoid, dose, product, or person. 1
Key takeaways
What to know first
Research areas
What researchers studied about Sleep onset latency
These are the main questions represented in the current literature. Each link opens a source used to build the overview.
Human research included
CBD
Researchers have studied CBD in connection with Sleep onset latency. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 2
Human research included
CBN
Researchers have studied CBN in connection with Sleep onset latency. The exact compound, dose, formulation, sleep or health measure, and study design determine what the source can show. 3
Results extracted so far
What did the studies report?
These summaries appear only when the recorded study outcome is specific enough to reproduce from the linked source. If a source has no result summary here, the result has not been extracted yet; that does not mean the study found no effect.
-
In a systematic review and meta-analysis of polysomnographic cannabis studies involving 18 studies identified; 9 included in meta-analysis, researchers did not detect a difference in consistent objective sleep-architecture improvement in a cannabis review following varied across included studies over varied across included studies. The recorded comparator was varied across included studies. 1
Recorded result: The review found no consistent alteration across objective sleep-architecture measures.
-
In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported fewer nighttime awakenings following 20 mg CBN over 7 nights. The recorded comparator was placebo. 2
-
In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers reported lower overall sleep disturbance following 20 mg CBN over 7 nights. The recorded comparator was placebo. 2
-
In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in sleep onset latency following 20 mg CBN over 7 nights. The recorded comparator was placebo. 2
-
In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in wake after sleep onset following 20 mg CBN over 7 nights. The recorded comparator was placebo. 2
-
In a double-blind randomized placebo-controlled study involving adults 18-55 with poor self-rated sleep quality, researchers did not detect a difference in daytime fatigue following 20 mg CBN over 7 nights. The recorded comparator was placebo. 2
-
In a double-blind randomized placebo-controlled multi-arm trial involving 293 adults with self-rated poor or very poor sleep quality, researchers did not detect a difference in augmentation of cbn sleep effects following 20 mg CBN with 10 mg, 20 mg, or 100 mg CBD nightly by the not stated in the PubMed abstract route over 7 nights. The recorded comparator was 20 mg CBN alone and placebo. 2
Recorded result: Adding CBD did not positively augment the CBN treatment effects.
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers did not detect a difference in wake after sleep onset following a single oral dose of 30 mg or 300 mg CBN. The recorded comparator was placebo. 3
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported shorter sleep onset latency following 300 mg CBN. The recorded comparator was placebo. 3
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported higher subjective sleep quality following 300 mg CBN. The recorded comparator was placebo. 3
-
In a randomized double-blind placebo-controlled crossover trial involving 20 adults with physician-diagnosed insomnia disorder, researchers reported more NREM-2 sleep following 300 mg CBN. The recorded comparator was placebo. 3
How strong is the research?
Not every study answers the same question
This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.
Human studies
Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.
Reviews and evidence summaries
Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.
Lab, animal, and mechanism research
Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.
What these studies actually looked at
The research on Sleep onset latency is not one kind of study. This source set includes 2 clinical studies in people and 1 systematic review or meta-analysis. 3
The recorded populations or models include 18 studies identified (1 source), 20 adults with physician-diagnosed insomnia disorder (1 source), and 293 adults with self-rated poor or very poor sleep quality (1 source). A result from one group or model should not be assumed to apply to another. 1
The most common recorded outcome focus is sleep onset latency (2 sources), daytime fatigue (1 source), and number of awakenings (1 source). Closely related outcome names can still describe different measurements. 2
Some source records specify doses including 20 mg CBN (1 source), 20 mg CBN with 10 mg, 20 mg, or 100 mg CBD nightly (1 source), and 300 mg CBN (1 source). These are descriptions of what researchers tested, not personal dosing instructions. 3
Examples from the literature
What did the studies actually look at?
Each example names the research question and the study details recorded for that source.
systematic review or meta-analysis
Cannabis and sleep architecture: A systematic review and meta-analysis.
On this page, this source examines CBD and consistent objective sleep-architecture improvement in a cannabis review. 1
- Study type
- systematic review or meta-analysis
- Population or model
- 18 studies identified
- Outcome focus
- polysomnographic sleep duration, latency, wake time, efficiency, and staging
- Dose recorded
- varied across included studies
- Evidence stage
- systematic review
clinical study in people
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality
On this page, this source examines CBN and nighttime awakenings, CBN and sleep onset latency, wake after sleep onset, or daytime fatigue, and CBN and overall sleep disturbance and other related questions. 2
- Study type
- clinical study in people
- Population or model
- adults 18-55 with poor self-rated sleep quality and 293 adults with self-rated poor or very poor sleep quality
- Outcome focus
- number of awakenings and sleep onset latency, wake after sleep onset, or daytime fatigue and other recorded details
- Dose recorded
- 20 mg CBN and 20 mg CBN with 10 mg, 20 mg, or 100 mg CBD nightly
- Evidence stage
- human research
clinical study in people
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial
On this page, this source examines CBN and wake after sleep onset, CBN and sleep onset latency, and CBN and subjective sleep quality and other related questions. 3
- Study type
- clinical study in people
- Population or model
- 20 adults with physician-diagnosed insomnia disorder
- Outcome focus
- polysomnography wake after sleep onset and sleep onset latency and other recorded details
- Dose recorded
- single oral dose of 30 mg or 300 mg CBN and 300 mg CBN
- Evidence stage
- human research
Safety and limits
What should readers keep in mind?
Research on Sleep onset latency should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2
Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.
Common questions
Questions people ask
Can cannabinoids help with Sleep onset latency?
Research exists, but there is not one answer for every cannabinoid or product. Human research is included, although its design and scope vary. 1
Why can studies reach different answers?
Studies may test different cannabinoids, doses, formulations, routes, people, and outcomes. Those differences can change the result. 2
What should I check in a study?
Check whether it studied people, what product and dose it used, what it measured, how long it lasted, and whether safety was reported. 3
Sources
Read the research
The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.
-
1
Cannabis and sleep architecture: A systematic review and meta-analysis. systematic review or meta-analysis; systematic review PubMed 40967124 DOI 10.1016/j.smrv.2025.102164
-
2
A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality clinical study in people; human research PubMed 37796540 DOI 10.1037/pha0000682
-
3
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research PubMed 41698831 DOI 10.1111/jsr.70284
See all 3 research sources
This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.
- A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality clinical study in people; human research / 7 linked research notes PubMed 37796540
- Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial clinical study in people; human research / 4 linked research notes PubMed 41698831
- Cannabis and sleep architecture: A systematic review and meta-analysis. systematic review or meta-analysis; systematic review / 1 linked research note PubMed 40967124